 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
| Adult:
As hydrochloride: initial 50-100 tid daily and slowly titrated upwards at no more than 100 mg weekly. |
| Max Dosage: 800 mg daily in 2-4 divided doses. |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
| Child:
2–12 yr: Initially, 0.5 mg/kg daily in divided doses, increased gradually until optimum effect obtained. |
| Max Dosage: 3 mg/kg daily. |
| |
| Oral |
| DEPRESSION WITH ANXIETY |
| Adult:
Initially, 25 mg tid, titrated to 20–200 mg daily. |
|
| |
|
| Precautions |
Pregnancy, lactation; renal or hepatic impairment, epilepsy. Perform ECG screening and electrolyte measurement before therapy, after each dose increase and at 6-month intervals. Monitor for visual defects on long-term therapy. May impair ability to perform skilled tasks. Withdrawal of drug to be carried out gradually over 1-2 wk. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Drowsiness, sedation, dry mouth, nasal congestion, blurring of vision, tremor, mydriasis, constipation, urinary retention, tachycardia, postural hypotension, sexual dysfunction, pigmentary retinopathy (high doses and prolonged therapy), contact dermatitis, tardive dyskinesias. |
| |
|
| Adverse Drug Reactions |
Neuroleptic malignant syndrome. Sudden deaths due to cardiac arrhythmias and arrest. |
| |
|
| Interactions |
Potentiates adverse effects of anticholinergics. Concurrent use of tricyclic antidepressants leads to raised blood levels of both drugs. Antagonised effects of levodopa, bromocriptine and other dopamine agonists. Avoid co-admin with drugs that cause electrolyte imbalance. Monitor phenytoin therapy due to inconsistent effects of thioridazine on phenytoin levels. |
| |
|
|
|
